Pharmaceuticals, Biotechnology & Life Sciences

EyePoint insider trades reveal short‑term tactics amid a growing retinal implant pipeline; see how these moves align with Phase III data, safety milestones, and future regulatory plans for EpiCure™ and gene therapy.

Repligen COO Bylund James buys back shares while selling to cover a PSU‑tax, signaling confidence in the company’s bioprocessing strategy amid a market decline.

Discover how insider trades at Ligand Pharmaceuticals reveal confidence in its drug‑delivery tech and NASH pipeline, hinting at future growth and potential regulatory wins.

RAPT Therapeutics insider sales reveal how a $58‑per‑share merger with GSK can shift short‑term price dynamics and long‑term growth prospects. Find out what investors should track for true value.

Ocugen insider buying signals optimism for gene‑therapy milestones: CFO’s stake consolidation, zero‑cost options and a robust pipeline suggest a path to profitability despite current losses.

RAPT Therapeutics’ insider sale ties into its merger with GSK‑linked Redrose, revealing structured RSU exits, robust reimbursement gains, and 12‑18 month clinical‑speed‑up prospects.

Insider buys signal confidence in FibroBiologics’ new osteoporosis patent, offering potential upside if clinical and regulatory milestones succeed.

Novavax insider purchase shows long‑term confidence in its VLP vaccine platform, highlighting positive market sentiment and potential for sustained shareholder value.

CEO’s disciplined share trades reveal confidence in Sotera’s growth, keeping investor ownership high while meeting tax needs.

Absci insider buying signals long‑term confidence, but a negative P/E and falling share price urge caution. Watch the March 24 earnings for validation.